| Upgrade to PrivCo Premium | or | $99 Single Company Access |
| Instant Full Site-Wide Access (includes access to all company, investor, and deal details) | Report on Private Company: Xencor, Inc. (includes access to this company and its deal details) |
|
|
| Date | Company | Series | Funding Amount |
| November 2000 | Xencor, Inc. | C | $50,000,000 |
| Upgrade to PrivCo Premium | or | $99 Single Company Access |
| Instant Full Site-Wide Access (includes access to all company, investor, and deal details) | Report on Private Company: Xencor, Inc. (includes access to this company and its deal details) |
|
|
| Round Details | |
| Funding Amount | $50,000,000 |
| Company Age At Funding | 3 years |
| Investor | Investor Type | Investment | Stake Acquired |
| Unspecified Investors |
| Financials for Xencor, Inc. | Valuation Multiples | ||
| Total Assets | N/A | V / A | |
| Stockholder's Equity | N/A | V / SE | |
| Revenues | N/A | V / R | |
| Net Income (Loss) | N/A | V / E | |
| Cash Flow | N/A | V / CF | |
| EBITDA | N/A | V / EBITDA | |
| Operating Income (Loss) | N/A | V / OI | |
| Business Description for Xencor, Inc. |
Xencor, Inc. is a privately held biotechnology company that engages in protein engineering technology platforms. It develops antibody and protein therapeutics to treat cancer and autoimmune inflammation. Founded in 1997, Xencor, Inc. is headquartered in Monrovia, California. |